Hans‐Michael Behrens

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients

Christine Böger, Hans‐Michael Behrens, Micaela Mathiak et al. · Oncotarget · 2016 · 283 citations · Full text

Esophageal Cancer, Immunology, Gastroenterology +17

The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?

Christine Böger, Hans‐Michael Behrens, Sandra Krüger et al. · OncoImmunology · 2017 · 153 citations · Full text

Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization

Micaela Mathiak, Viktoria S. Warneke, Hans‐Michael Behrens et al. · Applied immunohistochemistry & molecular morphology · 2015 · 143 citations · Full text

Elderly Patients, Instable Tumor Areas, Immunology +19

Amyloid in biopsies of the gastrointestinal tract—a retrospective observational study on 542 patients

Sophie Freudenthaler, Ute Hegenbart, Stefan Schönland et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2016 · 121 citations · Full text

Alzheimer's Disease, Functional Gastrointestinal Disorder, Medicine +8

Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study

Matthias Dottermusch, Sandra Krüger, Hans‐Michael Behrens et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2019 · 121 citations · Full text